08/07/2024 7:02 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/07/2024 7:04 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
06/10/2024 4:06 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting) BIOTECHNOLOGY VALUE FUND L P (Reporting) Biotechnology Value Trading Fund OS LP (Reporting) BVF GP HOLDINGS LLC (Reporting) BVF I GP LLC (Reporting) BVF II GP LLC (Reporting) BVF INC/IL (Reporting) BVF PARTNERS L P/IL (Reporting) BVF Partners OS Ltd. (Reporting) LAMPERT MARK N (Reporting) MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2024 3:40 PM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/06/2024 6:30 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/07/2024 7:01 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/07/2024 7:02 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
|
05/07/2024 6:57 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 10-K/A | |
04/24/2024 3:30 PM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form DEF 14A | |
04/24/2024 3:31 PM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form DEFA14A | |
04/24/2024 3:33 PM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form ARS | |
03/11/2024 7:01 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/29/2024 6:53 PM | MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer) Reich Kristian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 6:56 PM | MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer) Santos da Silva Jorge (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 7:03 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/29/2024 7:05 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/26/2024 8:00 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/22/2024 5:32 PM | MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer) Reich Kristian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/20/2024 5:36 PM | MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer) Santos da Silva Jorge (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/16/2024 5:02 PM | MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer) Reich Kristian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/15/2024 7:00 AM | Merck Healthcare KGaA (Filed by) MoonLake Immunotherapeutics (Subject) MoonLake Immunotherapeutics (Subject)
| Form SC 13G/A | |
02/14/2024 3:57 PM | CITADEL ADVISORS LLC (Filed by) MoonLake Immunotherapeutics (Subject) MoonLake Immunotherapeutics (Subject)
| Form SC 13G/A | |
02/09/2024 8:28 AM | FMR LLC (Filed by) MoonLake Immunotherapeutics (Subject) MoonLake Immunotherapeutics (Subject)
| Form SC 13G | |
12/20/2023 3:16 PM | Bodenstedt Matthias (Reporting) MoonLake Immunotherapeutics (Subject) MoonLake Immunotherapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/19/2023 3:34 PM | Bodenstedt Matthias (Reporting) MoonLake Immunotherapeutics (Subject) MoonLake Immunotherapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/06/2023 6:55 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/16/2023 5:16 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/04/2023 4:52 PM | Chen Bihua (Reporting) Cormorant Asset Management, LP (Reporting) Cormorant Global Healthcare Master Fund, LP (Reporting) Cormorant Private Healthcare Fund II, LP (Reporting) Cormorant Private Healthcare Fund III LP (Reporting) Cormorant Private Healthcare Fund IV LP (Reporting) MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/03/2023 6:27 PM | MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer) Reich Kristian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/03/2023 6:28 PM | MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer) Santos da Silva Jorge (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/03/2023 6:30 PM | Bodenstedt Matthias (Reporting) MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/03/2023 6:34 PM | MoonLake Immunotherapeutics (Issuer) MoonLake Immunotherapeutics (Issuer) Sturge Simon (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/11/2023 11:15 PM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form EFFECT | |
09/11/2023 10:59 AM | MoonLake Immunotherapeutics (Filer) MoonLake Immunotherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |